Clinical trials: Acute Cerebral Infarction
Brain Edema, Stroke, Acute
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
The primary objective of Part 1 of the study is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric…
- Trial name
- CHARM (NCT02864953)
- Testing
- BIIB093
- Where
- 250 sites in United States, Australia and 22 more
- Volunteers
- 535 people
- Sponsor
- Remedy Pharmaceuticals, Inc.
Acute Stroke, Cerebral Ischemia
A Study to Evaluate the Q Revascularization System for Neurointervention in Acute Ischemic Stroke
Assess the safety and efficacy of the Q Revascularization System to remove thrombi and emboli from the neurovasculature in patients experiencing an acute ischemic stroke
- Trial name
- EvaQ (NCT04437862)
- Testing
- Q Revascularization System
- Where
- 8 sites in United States, France
- Volunteers
- 121 people
- Sponsor
- MIVI Neuroscience, Inc.
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Brain Diseases, Cardiovascular Diseases
pRESET for Occlusive Stroke Treatment
Compare the safety and effectiveness of pRESET to Solitaire in the treatment of stroke related to large vessel occlusion
- Conditions
- Brain Diseases, Cardiovascular Diseases, Central Nervous System Diseases, Cerebrovascular Disorders
- Trial name
- PROST (NCT03994822)
- Testing
- Mechanical Thrombectomy using the pRESET Thrombectomy device, Mechanical Thrombectomy using the Solitaire Revascularization Device
- Where
- 24 sites in United States, Germany
- Volunteers
- 340 people
- Sponsor
- phenox Inc.
Stroke, Acute
A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke
This clinical trial was planned for the purpose to re-evaluate the safety and efficacy of naloxone hydrochloride in ischemic cerebral nerve disorders caused by stroke and cerebral hemorrhage.
- Trial name
- NCT05301712
- Testing
- Naloxone hydrochloride 5.0mg/5ml, Sodium Chloride 45mg/5ml
- Where
- South Korea
- Volunteers
- 446 people
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
Brain Ischemia, Stroke
Effects Of DP-b99 On Neurological Function In Subjects With Acute Ischemic Hemispheric Stroke
This study will examine if DP-b99 can improve neurological function (for example strength and coordination) in the 3 months after an acute stroke
- Conditions
- Brain Ischemia, Stroke, Cerebrovascular Disorders
- Trial name
- NCT00190047
- Testing
- DP-b99
- Where
- 22 sites in Germany, Israel
- Volunteers
- 150 people
- Sponsor
- D-Pharm Ltd.
Cerebral Ischemia
Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)
Safety and effect of SANGUINATE on patients DCI following SAH.
- Trial name
- NCT02323685
- Testing
- SANGUINATE™
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Prolong Pharmaceuticals
Cerebral Infarction
Cilostazol in Acute Ischemic Stroke Treatment (CAIST)
The purpose of this study is to study efficacy and safety of cilostazol use in patients with acute ischemic stroke.
- Trial name
- NCT00272454
- Testing
- Cilostazol, Aspirin
- Where
- 12 sites in South Korea
- Volunteers
- 468 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Stroke, Cerebral Ischemia
ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.
- Conditions
- Stroke, Cerebral Ischemia, Brain Infarction
- Trial name
- NCT00300196
- Testing
- Ancrod (Viprinex)
- Where
- 94 sites in United States, Australia and 9 more
- Volunteers
- 311 people
- Sponsor
- Neurobiological Technologies
Cardiovascular Disease, Myocardial Infarction
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial…
- Conditions
- Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
- Trial name
- EVOLVE-MI (NCT05284747)
- Testing
- Evolocumab, Routine Lipid Management
- Where
- 120 sites in United States, Brazil and 1 more
- Volunteers
- 6,019 people
- Sponsor
- Amgen
Ischemic Stroke
REperfusion With Cooling in CerebraL Acute IscheMia II
The primary objective of this study is to determine the feasibility and safety of achieving rapid hypothermia with the Proteus Intravascular Temperature Management (IVTM) system for patients experiencing acute ischemic stroke due…
- Trial name
- RECCLAIM-II (NCT03804060)
- Testing
- Thermogard XP3, Recanalization only
- Where
- 8 sites in United States
- Volunteers
- 90 people
- Sponsor
- ZOLL Circulation, Inc., USA
Ischemic Stroke
Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment…
- Trial name
- RODIN (NCT05041010)
- Testing
- Neu2000KWL group
- Where
- 24 sites in South Korea
- Volunteers
- 496 people
- Sponsor
- GNT Pharma
Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months
An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding
This study is to evaluate the incidence rate of Major Adverse CardioCerebrovascular Events(MACCE) in Patients with Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the secondary prevention and Esomezol Cap for…
- Trial name
- NCT05487560
- Testing
- Esomezol Cap
- Where
- South Korea
- Volunteers
- 4,133 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Stroke, Acute, Stroke, Ischemic
Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial
The objective of the MEDIS study is to determine if subjects experiencing an Acute Ischaemic Stroke due to large vessel occlusion, treated with IV tPA combined with the MED procedure have a greater likelihood of recanalisation…
- Conditions
- Stroke, Acute, Stroke, Ischemic, Infarction, Middle Cerebral Artery, Strokes Thrombotic
- Trial name
- MEDIS (NCT03098732)
- Testing
- Magnetically Enhanced Diffusion (MED)
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Pulse Therapeutics
Ischemic Stroke
Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke
The primary objective of this study is to further define the mechanisms of action of Mexidol® (solution for intravenous and intramuscular injection, 50 mg/ml) and Mexidol® FORTE 250 (film-coated tablets, 250 mg) in the hyperacute…
- Trial name
- NCT07575984
- Testing
- Mexidol, Glycine
- Where
- 9 sites in Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Pharmasoft
Acute Myocardial Infarction, Restenoses, Coronary
Abbott Vascular Medical Device Registry
The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use…
- Conditions
- Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism
- Trial name
- AV-MDR (NCT04573660)
- Testing
- Coronary and peripheral stents, Pacing catheters, Vascular plugs
- Where
- 37 sites in United States, Australia and 12 more
- Volunteers
- 3,784 people
- Sponsor
- Abbott Medical Devices
Acute Ischemic Stroke, Partial Anterior Circulation Infarct
DLBS1033 for Acute Ischemic Stroke Patients
This is a prospective, randomized, double-blind, and controlled clinical study to investigate the effects of DLBS1033 in conjunction with standard therapy compared to standard therapy alone in acute ischemic stroke patients.
- Conditions
- Acute Ischemic Stroke, Partial Anterior Circulation Infarct, Lacunar Anterior Circulation Infarct
- Trial name
- ADDLIST (NCT02133521)
- Testing
- DLBS1033
- Where
- 10 sites in Indonesia
- Volunteers
- 80 people
- Sponsor
- Dexa Medica Group
Stroke
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）
The purpose of this study is to confirm the efficacy and safety of intravenously administered alteplase in patients with acute ischemic stroke based on the rate of recanalization assessed by magnetic resonance angiography (MRA)…
- Trial name
- NCT00412867
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 58 people
- Sponsor
- Tanabe Pharma Corporation
Acute Coronary Syndrome
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death…
- Trial name
- AEGIS-II (NCT03473223)
- Testing
- Apolipoprotein A-I [human] (apoA-I)
- Where
- 903 sites in United States, Argentina and 47 more
- Volunteers
- 18,226 people
- Sponsor
- CSL Behring
Acute Stroke, Cerebral Ischemia
PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients
This was a prospective, multicentric, randomized, double blind, parallel, saline controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide) therapy along with standard supportive care in…
- Trial name
- NCT04046484
- Testing
- Normal Saline along with standard treatment, PMZ-1620 along with standard treatment
- Where
- 7 sites in India
- Volunteers
- 40 people
- Sponsor
- Pharmazz, Inc.